CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 220 enrolled
Drug / intervention
Varenicline +1 moredrug
Likely dose
Varenicline 0.5 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00595868
NCT00595868Phase 2Completed
CompareCT.gov

Efficacy of Varenicline in Ambivalent Smokers

University of Vermont Medical Center·interventional·Posted Jan 16, 2008·Updated Dec 2, 2011

In Brief

A Phase 2 clinical trial evaluating Varenicline and Placebo for Tobacco Use Disorder and 2 related conditions. Completed, enrolled 220 participants across 2 sites.

Detailed Summary

The purpose of this study is to test whether Varenicline can help ambivalent smokers (those who are interested in quitting at some point in the future but have no current plans to quit) to reduce their smoking and eventually quit.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTobacco Use Disorder, Tobacco Use Cessation, Nicotine Dependence
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 16, 2008
Enrollment StartMar 1, 2008
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.5 years ago

Interventions

Vareniclinedrug

0.5 milligrams two times per day for 3 days, then 1.0 milligrams two times per day for an addition 11 days - 2 months

Placebodrug

same as Varenicline arm